Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Geologica Closes Financing And Property Acquisition (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Traws Pharma Inc TRAW

Healthcare
Traws Pharma, Inc., formerly Onconova Therapeutics, Inc., is a virology and oncology company. The Company is engaged in developing antivirals for influenza, COVID and other respiratory infections and narazaciclib. Its proprietary portfolio includes, TRX100 (viroksavir), TRX01 (travaltrevir), and Narazaciclib. Viroksavir is a cap-dependent endonuclease inhibitor for influenza. Travaltrevir is a... see more

Recent & Breaking News (NDAQ:TRAW)

Onconova Therapeutics Announces Registered Direct Offering

GlobeNewswire January 6, 2016

Onconova to Host Myelodysplastic Syndromes (MDS) Key Opinion Leader Meeting on Wednesday, December 16, in New York City

GlobeNewswire December 14, 2015

Onconova Presents Positive Data From Phase 2 Combination Trial of Oral Rigosertib and Azacitidine in Higher-Risk Myelodysplastic Syndromes at 2015 ASH Annual Meeting

GlobeNewswire December 7, 2015

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Onconova Therapeutics, Inc. - ONTX

Accesswire December 7, 2015

Onconova Enrolls First Patient in Phase 3 INSPIRE Trial of Rigosertib

GlobeNewswire December 7, 2015

Onconova Therapeutics, Inc. to Participate in Panel Discussions at Two Investor Conferences in December

GlobeNewswire November 25, 2015

Onconova Therapeutics, Inc. Reports Recent Business Highlights and Third Quarter 2015 Financial Results

GlobeNewswire November 11, 2015

Onconova Announces Data Presentation From Phase 2 Combination Trial of Oral Rigosertib and Azacitidine at the 2015 ASH Annual Meeting

GlobeNewswire November 5, 2015

Onconova Therapeutics, Inc. to Present New Data on Briciclib and Next-Generation CDK4/6 Inhibitor, ON 123300, at 2015 AACR-NCI-EORTC Meeting

GlobeNewswire October 29, 2015

Onconova Therapeutics Announces $16.5M Share Purchase Agreement With Lincoln Park Capital Fund

GlobeNewswire October 8, 2015

Onconova Therapeutics, Inc. to Present Corporate Update at Rodman & Renshaw 17th Annual Global Investment Conference

GlobeNewswire September 2, 2015

Onconova Therapeutics Files European Clinical Trial Applications for Global Phase 3 Trial for IV Rigosertib in Higher-Risk Myelodysplastic Syndromes

GlobeNewswire August 27, 2015

Onconova Therapeutics Announces Submission of Investigational New Drug Application for Pivotal Phase 3 Trial for IV Rigosertib in Higher-Risk Myelodysplastic Syndromes

GlobeNewswire August 13, 2015

Onconova Therapeutics, Inc. Reports Recent Business Highlights and Second Quarter 2015 Financial Results

GlobeNewswire August 13, 2015

Onconova Appoints James J. Marino, Esq. to Board of Directors

GlobeNewswire July 8, 2015

Onconova Therapeutics, Inc. to Present Corporate Update at the Cantor Fitzgerald Healthcare Conference

GlobeNewswire July 1, 2015

Onconova to Host Myelodysplastic Syndromes (MDS) Key Opinion Leader Meeting on Tuesday, June 30 in New York City

GlobeNewswire June 23, 2015

Onconova Presents Patient Selection Criteria and Intermediate Clinical Endpoints for Rigosertib in Higher-Risk Myelodysplastic Syndromes (HR-MDS) at EHA Annual Meeting

GlobeNewswire June 15, 2015

Onconova Presents Clinical Data on Rigosertib in Higher-Risk Myelodysplastic Syndromes (HR-MDS) at the 2015 ASCO Annual Meeting

GlobeNewswire June 1, 2015

Onconova Therapeutics, Inc. Reports Recent Business Highlights and First Quarter 2015 Financial Results

GlobeNewswire May 14, 2015